Navigation Links
Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
Date:2/19/2009

s. This study suggests that Novavax's recombinant VLP technology may be utilized for development of a vaccine capable of inducing broad cross protection against a variety of strains with pandemic potential without the use of an adjuvant. "It is extremely important to identify a pre-pandemic vaccine candidate which is able to protect against different antigenic variants of H5N1 virus that are circulating broadly," said Dr. Honglin Chen.

H5N1 avian influenza viruses emerged in humans in Hong Kong in 1997 and have been associated with a mortality of 62% among confirmed cases according to a World Health Organization February 2009 report. Clades 2.1, 2.2, and 2.3 are genetically and antigenically distinct viruses that are circulating in wild birds and poultry worldwide and continue to be associated with human illness. "We believe that our recombinant VLP technology has the potential to be a powerful, new approach to develop broadly cross-protective vaccines. This approach may provide a viable strategy for pre-pandemic vaccination without an adjuvant and for stockpiling of vaccine to be utilized during the first wave of an influenza pandemic," said Dr. Rahul Singhvi, President and CEO of Novavax, Inc. Further studies of the new VLP will be conducted in ferrets and methods of inducing protection against even more divergent strains (e.g., against different HA types) will be explored.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Com
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
7. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
11. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... EXTON, Pa., Dec. 14 BioTrends Research ... Arthritis, a syndicated publication offering comprehensive insight ... report is based on a comparison of self-reported ... actual patient level data for over 1,000 RA ... agents. ,, To be eligible for the audit, ...
(Date:12/14/2009)... is a statement by Linda A. Suydam, D.P.A., ... regarding today,s release of the National Institute on ... "Findings released today on this year,s Monitoring the ... efforts to educate and empower parents with the ... about medicine abuse. The Consumer Healthcare Products Association ...
(Date:12/14/2009)... Corgenix Medical Corporation (OTC Bulletin Board: CONX), ... test kits, and BG Medicine, Inc. (BGM), ... today a supply agreement whereby Corgenix will ... immunosorbent assay (ELISA) microtiter format exclusively for ... clearance in the United States of the ...
Breaking Medicine Technology:New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis 2New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis 3Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 2Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 3Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM) 2Chief Medical Officer Joins Aon Consultings Health 26 Benefits Practice 51226 1Chief Medical Officer Joins Aon Consultings Health 26 Benefits Practice 51226 2Chief Medical Officer Joins Aon Consultings Health 26 Benefits Practice 51226 3Oral Piercings Pose Potential Health Care Risks 51221 1Oral Piercings Pose Potential Health Care Risks 51221 2Oral Piercings Pose Potential Health Care Risks 51221 3UT Southwestern UT Arlington to develop magnetic surgery tools 51218 1UT Southwestern UT Arlington to develop magnetic surgery tools 51218 2UT Southwestern UT Arlington to develop magnetic surgery tools 51218 3
... thrombosis after two years in,high-risk patient population, ... 2007,/PRNewswire-FirstCall/ -- Boston Scientific Corporation today,announced four-year ... The data demonstrated that the safety and ... the TAXUS(R),Express(TM) paclitaxel-eluting stent system -- which ...
... analysis shows no stent thrombosis or MACE,after ... May 22, 2007,/PRNewswire-FirstCall/ -- Boston Scientific Corporation ... the SPIRIT FIRST, II,and III Clinical Trials, ... market-leading TAXUS(R) Express2(TM) Paclitaxel-Eluting,Coronary Stent System and ...
Other Medicine Technology:Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 2Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 3SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus,Drug-Eluting Coronary Stent Systems 2SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus,Drug-Eluting Coronary Stent Systems 3
(Date:12/15/2009)... "The entire San Diego Hospice and The ... Sol Price on December 14, 2009. Mr. Price has ... and ethics in his business, community and personal life. ... truly understood the responsibility of philanthropy and the role ... live on through his countless philanthropic efforts. We extend ...
(Date:12/14/2009)... OAK BROOK, Ill., Dec. 15 In ... a larger role than ever. Now the University ... noteworthy resources, Value Analysis: Achieving Cost Efficiencies ... staff in these complex environments. These new materials, ... in the field, provide a practical guide to ...
(Date:12/14/2009)... -- Americold Realty Trust ("Americold") announced today that it ... the U.S. Securities and Exchange Commission (the "SEC") relating ... shares. The number of shares to be offered and ... been determined. The common shares to be sold in ... ,, The joint book-running managers of the offering ...
(Date:12/14/2009)... -- United Dental Care (also known as Culver ... top-notch dental care in Southern California. We provide treatments ... braces (orthodontics) and periodontal treatments. Beverly Hills Dentist ... are staffed with experienced and trusted dentists who provide ... (Dr. E) is one of these trusted dentists. He ...
(Date:12/14/2009)... ... La Jolla, Calif. (Vocus) -- The physicians at Scripps ... new chief of staff of the 372-bed facility. Dr. Sedwitz will ... 1, 2010. , , , , ,During his two-year term, Dr. ... administrative staff and its board of directors. Dr. Sedwitz will play ...
Breaking Medicine News(10 mins):Health News:San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price 2Health News:University HealthSystem Consortium Offers Value Analysis Professionals Insightful New Resources 2Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2Health News:United Dental Care, Gentle Care, Trusted Dentists 2Health News:United Dental Care, Gentle Care, Trusted Dentists 3Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3
... SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: ... for infectious,diseases, has received preliminary four-week interim results ... C virus ("HCV") treatment-naive,patients which indicate that celgosivir ... effects on the tolerability, pharmacokinetics,and viral kinetics when ...
... 3 /PRNewswire-FirstCall/-- Alfacell Corporation,(Nasdaq: ACEL ) today ... and,Webcast at 11 a.m. EST on Monday, Dec. ... chief executive officer, and Lawrence A. Kenyon,chief operating ... of Alfacell,s financial performance for the fiscal first ...
... Inc. (Amex: PLX ), noted today that ... which is used as,an enzyme replacement therapy for ... Promising Drugs Entering Phase III Trials in the ... published by Thomson Scientific. Thomson,Scientific, a part of ...
... with National Quality/Patient Safety Initiatives; Geared to Reducing ... Errors, Enhancing Operating Room Efficiencies, LAKE FOREST, ... provider of outsourced hospital compounded sterile preparations, is,offering ... devoted to reducing medication errors and improving OR,efficiencies. ...
... 3 No longer are helmets,enough for motorcyclists ... book, Motorcycle Cancer?, author Randall Dale,Chipkar considers motorcycle ... riders may have a higher risk for cancer ... legs," says,Chipkar. "Is it a paradox that thousands ...
... and their ... employees, CHICAGO, Dec. ... care costs and help employees,identify their health risks and cut back on ... smoking cessation,plans and counseling to discounted gym memberships and even acupuncture --,can ...
Other Medicine News:Health News:MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study 2Health News:MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study 3Health News:MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study 4Health News:MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study 5Health News:MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study 6Health News:Alfacell to Host Fiscal First Quarter 2008 Financial Results Conference Call and Webcast 2Health News:Protalix BioTherapeutics' prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific 2Health News:Protalix BioTherapeutics' prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific 3Health News:PharMEDium Announces Availability of Pre-Filled Operating Room Perioperative Compounded Drugs 2Health News:Motorcycle Radiation May Be Linked to Cancer Risk 2Health News:Employee Health Includes Financial Health, Too 2
... can trust its capabilities will expand ... and glaucoma therapy in one system. ... the optimal system for photocoagulation, post-cataract ... The push of a button is ...
... YAG III is the new disruption ... in particular for applications in posterior ... the YAG laser is also used ... IOL polishing. It's another milestone in ...
... MEL 80 is a top quality Carl ... correction of vision defects even safer, more ... this ultramodern work platform are oriented towards ... the rapid recovery of vision. Key factors ...
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
Medicine Products: